FDA Brief

Warning letters Drugs

FDA warning letter to

Suhan Aerosol

High riskIssued Aug 3, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

What happened

FDA reviewed records Suhan Aerosol submitted after the agency's January 25, 2023 request under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act; there was no inspection. FDA found the firm did not test each shipment and lot of high-risk components such as glycerin, propylene glycol, and sorbitol for identity and for diethylene glycol (DEG) or ethylene glycol (EG) contamination. FDA also found the quality unit did not effectively approve or reject components, and the firm was placed on Import Alert 66-40 on March 30, 2023.

What FDA found

  1. Suhan Aerosol did not test each incoming lot of high-risk components such as glycerin, propylene glycol, and sorbitol to verify identity and detect diethylene glycol (DEG) or ethylene glycol (EG) contamination.

    21 CFR 211.84(d)(1)
  2. Suhan Aerosol's quality unit did not effectively exercise its authority to approve or reject components in the materials system.

    21 CFR 211.22(a)

What FDA wants

FDA tells Suhan Aerosol to respond in writing within 30 working days with corrective actions and to provide DEG/EG test results within 30 calendar days. If corrective actions cannot be completed within 15 working days, the firm must state why and give a completion schedule.

Who should pay attention

  • brands that buy OTC drugs or personal-care products from Suhan Aerosol
  • companies sourcing children's toothpaste or hand sanitizer from contract manufacturers
  • buyers and suppliers of glycerin, propylene glycol, or sorbitol

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  3. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  4. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk